



Value of Cancer Immunotherapy Summit

Organized in collaboration with the American Society of Clinical Oncology (ASCO)

Sunday, November 13, 201

Non CE-session

Co-Chairs:

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Lowell E. Schnipper, MD – *Beth Israel Deaconess Medical Center*

Peter P. Yu, MD, FACP, FASCO – *Hartford HealthCare Cancer Institute*

7:45 – 7:50 a.m.

Annual Meeting Organizer Welcome

James L. Gulley, MD, PhD, FACP – *National Cancer Institute, National Institute of Health*

7:50 – 8:00 a.m.

Program Introduction

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Session I: Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective

8:00 – 8:30 a.m.

Evaluation of Current Value Models

Peter P. Yu, MD, FACP, FASCO – *Hartford HealthCare Cancer Institute*

8:30 – 8:45 a.m.

Cancer Immunotherapy Perspective on Current Value Models

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

8:45 – 9:05 a.m.

Economic Outcomes of Cancer Therapy: ISPOR Initiatives on U.S. Value Assessment Framework

Lou Garrison, PhD, AB – *University of Washington*

9:05 – 9:25 a.m.

Patient Perspective

Steven Silverstein, MBA – *Melanoma Research Foundation*

9:25 – 9:45 a.m.

Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer

Adam P. Dicker, MD, PhD – *Thomas Jefferson University*

Heather S. Jim, PhD – *H. Lee Moffitt Cancer Center & Research Institute*

9:45 – 10:10 a.m.

Panel Discussion

Moderator:

Howard L. Kaufman, MD, FACS – *Rutgers Cancer Institute of New Jersey*

Panelists:

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Adam P. Dicker, MD, PhD – *Thomas Jefferson University*

Lou Garrison, PhD, AB – *University of Washington*

Heather S. Jim, PhD – *H. Lee Moffitt Cancer Center & Research Institute*

Steven Silverstein, MBA – *Melanoma Research Foundation*

Peter P. Yu, MD, FACP, FASCO – *Hartford HealthCare Cancer Institute*



Session II: Perspectives on the Value of Cancer Immunotherapy

- 10:10 – 10:30 a.m. **Payor Perspective**
William McGivney, PhD – *McGivney Global Advisors*
- 10:30 – 10:50 a.m. **Industry Perspective**
Jon M. Wigginton, MD – *MacroGenics, Inc.*
- 10:50 – 11:10 a.m. **Predictive and Companion Biomarkers**
Roy S. Herbst, MD, PhD – *Yale Cancer Center*
- 11:10 – 11:55 a.m. **Panel Discussion**
Moderator:
Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*
- Panelists:*
Kirsten Axelsen, MS – *Pfizer*
Daniel S. Chen, MD, PhD – *Genentech*
Ravinder Dhawan, PhD – *Merck & Co*
Roy S. Herbst, MD, PhD – *Yale Cancer Center*
Gregory Keenan, MD – *AstraZeneca*
William McGivney, PhD – *McGivney Global Advisors*
Jon M. Wigginton, MD – *MacroGenics, Inc.*
- 11:55 – noon **Closing Remarks**